Isentress (raltegravir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  

32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
ACTRN12609000881235: A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2-3 nucleoside reverse transcriptase inhibitors (NRTI) backbone versus ritonavir boosted lopinavir and raltegravir in participants virologically failing first-line non-nucleoside reverse transcriptase inhibitors (NNRTI)/2 NRTI therapy (the SECOND-LINE study). This study is for Human Immunodeficiency Virus (HIV) infection.

Active, not recruiting
4
550
 
University of New South Wales/Kirby Institute, University of New South Wales/Kirby Institute, Abbott, Merck Sharpe & Dohme, amfAR
Human Immunodeficiency Virus (HIV) -1 infection
 
 
2011-005270-35: Study of the effect of pregnancy on the concentrations of antiretroviral drugs in the blood of women with HIV infection Studio dell'effetto della gravidanza sulle concentrazioni dei farmaci antiretrovirali nel sangue di donne con infezione da HIV

Ongoing
4
120
Europe
Tablet, Capsule, soft, Capsule, hard, Film-coated tablet, VIRAMUNE*60CPR 200MG, COMBIVIR*FL 60CPR RIV, KALETRA*120CPR RIV 200MG+50MG, REYATAZ*60CPS 150MG, TRUVADA*30CPR RIV 200MG/245MG, PREZISTA*60CPR RIV 600MG, ISENTRESS*FL 60CPR RIV 400MG, NORVIR*FL 84CPS MOLLI 100MG
ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI, Istituto Superiore di Sanita'
HIV-1 infection Infezione da HIV-1, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02]
 
 
2014-003710-84: The CNS Integrase Inhibitor Study

Ongoing
4
22
Europe
Tivicay, Isentress, Truvada, Film-coated tablet, Tivicay, Isentress, Truvada
Imperial College London
Human Immunodificiency Virus, HIV, Diseases [C] - Virus Diseases [C02]
 
 
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA.

Ongoing
4
450
Europe
Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ
Fundació Lluita contra la SIDA, Fundació Lluita contra la SIDA
Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
2008-001611-38: Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1

Ongoing
4
10
Europe
Isentress, Aptivus, Norvir, raltegravir, tipranavir, ritonavir, Isentress, Aptivus, Norvir, Isentress, Aptivus, Norvir
Jose M Gatell - Hospital Clinic de Barcelona
Pacientes con infección crónica por VIH-1
 
 
2009-013679-23: étude cas-témoins comparant l\'efficacité d’une combinaison thérapeutique contenant l\'inhibiteur de l\'intégrase raltégravir (400 mg x 2) ou une combinaison thérapeutique ne contenant pas le raltégravir sur la diminution de l\'ADN proviral chez des sujets prétraités présentant une infection par le VIH-1 avec une charge virale détectable

Ongoing
4
60
Europe
Raltegravir, J05AX08, Raltegravir, Raltegravir
STOP SIDA
Patients âgés de plus de 18 ans, infectés par le VIH et traités par Raltégravir.
 
 
2014-004578-40: SSAT 066 Renal Integrase Study

Not yet recruiting
4
60
Europe
Tivicay 50 mg film - coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets, Film-coated tablet, Tivicay 50 mg film-coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets
St Stephen's AIDS Trust, Merck, Sharp & Dohme Limited
HIV
 
 
2016-000437-43: The time to protection and adherence requirements of Raltegravir with or without lamivudine in protection from HIV infection

Not yet recruiting
4
36
Europe
Raltegravir, Lamivudine, Tablet, Film-coated tablet, Raltegravir, Lamivudine
Guy's and St Thomas NHS Foundation Trust, Merck Sharp & Dhome Ltd
HIV, HIV, Diseases [C] - Virus Diseases [C02]
 
 
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos.

Ongoing
4
100
Europe
lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy
FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare
HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
2017-003470-14: Raltegravir One Thousand two hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study Raltegravir 1200 versus Darunavir-cb en pacientes inmunodeprimidos: estudio ROTDIP

Not yet recruiting
4
75
Europe
Film-coated tablet, , ISENTRESS
FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, APES Costa del Sol (Agencia Pública Empresarial Sanitaria Costa del Sol), MSD Merck Sharp & Dohme, MSD MErck Sharp & Dohme
Human Immunodeficiency Virus (HIV) infection Infección por el Virus de Inmunodeficiencia Humana (VIH), Human Immunodeficiency Virus (HIV) infection Infección por el Virus de Inmunodeficiencia Humana (VIH)., Diseases [C] - Virus Diseases [C02]
 
 
NCT04258475: The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

Recruiting
4
12
Canada
Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily., RAL, Isentress®, Calcium carbonate antacid tablet, TUMS® Ultra Strength (US) 500 mg
Ottawa Hospital Research Institute
Calcium Supplementation in HIV Patients Using Raltegravir
06/24
01/25
PANNA-B PK, NCT05648201: Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers

Recruiting
4
36
Europe
Doravirine 100Mg Tab, pifeltro, Raltegravir 600Mg Tab, issentres, Biktarvy 50/200/25 Tab, biktarvy
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Merck Sharp & Dohme LLC
Hiv
11/24
12/24
ACTRN12609000575235: Antiretroviral therapy intensification with raltegravir and/or hyper-immune bovine colostrum in Human Immunodeficiency Virus-1 (HIV-1) infected patients with suboptimal immunological response

Active, not recruiting
3/4
72
 
University of New South Wales (UNSW), National Centre in HIV Epidemiology and Clinical Research University of New South Wales (UNSW)
Human Immunodeficiency Virus (HIV)Infection
 
 
NCT00717964: Study of Raltegravir Versus Nucleotide Reverse Transcriptase Inhibitors (NRTIs) as a Backbone in HIV-Infected Subjects Switched From a Stable Boosted Protease Inhibitor (PI) Regimen

Active, not recruiting
3
34
US
Raltegravir, Isentress, current antiretroviral regimen
St. Joseph's Hospital, Florida
HIV Infections
07/11
10/11
2007-000783-25: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA™-Based Regimen - Study A

 
3
32
Europe
Kaletra (Lopinavir Ritonavir), MK-0518, KALETRA, KALETRA
Merck Sharp & Dohme de España, S.A., Merck & Co., Inc., Merck Sharp & Dohme Limited, MERCK SHARP DOHME, Merck Sharp & Dohme, Lda.
HIV Infection
 
12/08
2008-002733-70: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients

 
3
65
Europe
ISENTRESS, TRUVADA, MK-0518, ISENTRESS, TRUVADA, ISENTRESS, TRUVADA
Merck & Co., Inc., Merck & Co Inc.,, Merck & Co. Inc., Laboratoires Merck Sharp & Dhome-Chibret, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK & CO., INC., MSD BV
HIV infection
 
05/11
2010-018878-21: A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir

Ongoing
3
40
Europe
Isentress, Truvada (tenofovir disoproxil/emtricitabine), Isentress, Truvada, Isentress, Truvada
St Stephen\'s AIDS Trust
HIV
 
 
2019-001961-34: ANRS 173 ALTAR (ALlégement du Traitement AntiRétroviral) ANRS 173 ALTAR (ALlégement du Traitement AntiRétroviral)

Not yet recruiting
3
360
Europe
Film-coated tablet, , VIREAD or Tenofovir disoproxil fumarate (generic drug), STRIBILD 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil fumarate or 136 mg of tenofovir), BIKTARVY bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide., ISENTRESS, TIVICAY, DESCOVY 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide, GENVOYA 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide, EPIVIR or Lamivudine (generic drugs), TRUVADA or Emtricitabine and tenofovir disoproxil fumarate (Generic drug)
INSERM ANRS, ANRS
Hiv Infection Infection par le VIH, Hiv Infection Infection par le VIH, Diseases [C] - Virus Diseases [C02]
 
 
2008-004970-41: Phase II open-label randomized multicenter trial to compare the efficacy and safety of two different doses of raltegravir and efavirenz, all in combination with tenofovir and lamivudine, in naive HIV-1-infected patients receiving rifampin for active tuberculosis.

Ongoing
2
15
Europe
Sustiva, Viread, Epivir, MK-0518, BMS-561525, raltegravir, Sustiva, Viread, Epivir, Isentress, Sustiva, Viread, Epivir, Isentress
Agence nationale de recherches sur le sida et les hépatites virales. ANRS.
HIV-1 Infection and tuberculosis
 
 
2009-016480-11: “No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected by CCR5 HIV-1

Ongoing
2
40
Europe
Raltegravir, Maraviroc, Tenofovir/Emtricitabine, ISENTRESS, CELSENTRI, TRUVADA, ISENTRESS, CELSENTRI, TRUVADA
P Pierre Dellamonica
HIV naïve patients, CCR5 tropism, with CD4 > 200/mm3 and HIV RNA < 100 000 copy/ml.
 
 
2009-014406-34: International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression

Ongoing
2
12
Europe
GLYCOSYLATED RECOMBINANT HUMAN INTERLEUKIN-7, MARAVIROC, RALTEGRAVIR, CYT107, SELZENTRY, CELSENTRI, ISENTRESS, SELZENTRY, CELSENTRI, ISENTRESS
ORVACS, KEYRUS BIOPHARMA, , Bettencourt-Schueller Foundation
HIV-1 Infection
 
 
RIVER, NCT02336074 / 2014-001425-32: Research In Viral Eradication of HIV Reservoirs

Completed
2
60
Europe
Combination Antiretroviral Therapy (cART), Raltegravir, Isentress, Vorinostat, ChAdV63.HIVconsv (ChAd), MVA.HIVconsv (MVA)
Imperial College London, Medical Research Council, University of Oxford, University of Cambridge, Chelsea and Westminster NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, Brighton and Sussex University Hospitals NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Central and North West London NHS Foundation Trust
HIV
11/17
03/23
2019-004195-19: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regimen

Not yet recruiting
2
150
Europe
Isentress, Pifeltro, J05AX08, J05AR24, Tablet, ISENTRESS, Pifeltro
Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS), Centre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS), CREPATS, Centre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS)
HIV disease, HIV disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT03954327: Combination Antiretroviral Therapy (cART) for PBC

Completed
2
37
Canada
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Truvada, Raltegravir, Isentress, Placebo Oral Capsule [CEBOCAP], placebo
University of Alberta, Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
10/22
01/24
DORAL, NCT04513626: HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label

Recruiting
2
150
Europe
DORAVIRINE 100 MG [Pifeltro], Raltegravir 600 Mg x 2 [Isentress]
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infections
10/24
10/24
NCT02140255: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting
1/2
1120
US, RoW
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, DTG, VRC07-523LS
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
HIV Infection
01/28
12/31
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR

Recruiting
1
10
US
18F-Raltegravir
University of California, San Francisco, Merck Sharp & Dohme LLC
HIV-1-infection
11/24
01/25
POPARV, NCT03194165: Population Pharmacokinetics of Antiretroviral in Children

Completed
N/A
65
Europe
Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
Assistance Publique - Hôpitaux de Paris
Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed
06/22
06/22
RalAge2, NCT03579485: An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge)

Recruiting
N/A
90
Europe
Azienda Policlinico Umberto I
Hiv
12/23
12/24
EPPICC, NCT05751031: Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration

Recruiting
N/A
1200
Europe, RoW
Raltegravir
Fondazione Penta UK, UCL Great Ormond Street Institute of Child Health
HIV Infections
02/24
02/24
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study

Recruiting
N/A
2017
Europe
Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen
University of Zurich
HIV Infections
01/25
01/25
ACTRN12608000177358: An open label study to examine the characteristics of Human Immunodeficiency Virus (HIV) decay following introduction of combination antiretroviral therapy including raltegravir during primary and chronic HIV infection

Active, not recruiting
N/A
16
 
National Centre in HIV Epidemiology and Clinical Research, National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales (UNSW), Merck, Sharp and Dohme
Primary HIV (acute or early), Chronic HIV infection
 
 

Download Options